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Summary
Objective: To determine the efficacy and safety of colistin (colistimethate sodium) produced by a
local pharmaceutical company in Thailand for the treatment of infections caused by multidrug-
resistant (MDR) Pseudomonas aeruginosa and Acinetobacter baumannii.
Methods: Patients hospitalized at Siriraj Hospital between January 2005 and April 2006, who had
infections caused by MDR P. aeruginosa or A. baumannii, were enrolled in the study. Colistin
(colistimethate sodium) at a dosage of 5 mg/kg/day was given intravenously in two divided doses.
Primary outcomes were the clinical response and 30-day mortality; secondary outcomes were
microbiological response and adverse events.
Results: Ninety-three patients infected with MDR P. aeruginosa and A. baumannii were enrolled.
Seventy-eight patients (71 with A. baumannii and seven with P. aeruginosa) received colistin,
whereas 15 patients (12 with A. baumannii and three with P. aeruginosa) received other
antibiotics. The mean age, gender, underlying conditions and severity of illness of the patients
in both groups were not significantly different. In the colistin group, 63 patients (80.8%) had a
favorable clinical response and 94.9% had a microbiological response. The overall mortality of the
patients in the colistin groupwas 46.2% and that in the non-colistin group was 80%. Nephrotoxicity
was found in 24 patients (30.8%) in the colistin group and 17 of them had predisposing factors
contributing to their renal dysfunction. No neurotoxicity was observed among the 78 patients.* Corresponding author. Tel.: +66 2 412 5594; fax: +66 2 412 5994.
E-mail address: visanut@yahoo.com (V. Thamlikitkul).
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Conclusion: Locally produced colistin appears to be safe and effective for the treatment of
infections caused by MDR P. aeruginosa and A. baumannii in Thai adult patients.
# 2006 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
Nosocomial infections caused by multidrug-resistant (MDR)
organisms are emerging worldwide.1—3 The incidence of MDR
pathogens, particularly Acinetobacter baumannii and Pseu-
domonas aeruginosa, in Thailand has dramatically
increased.4 A prospective cohort study of 208 clinical isolates
of A. baumannii recovered from the patients in Siriraj Hos-
pital from January to December 2002, revealed that 86
strains (41.3%) were isolated from the infected patients
and the remaining 58.7% were colonizers.5 In this study,
57% of A. baumannii isolates were resistant to all antimicro-
bial agents available in Thailand including beta-lactams,
aminoglycosides and fluoroquinolones, and the overall mor-
tality rate of the patients infected with pandrug-resistant A.
baumannii was 79%.5 The study of 104 clinical isolates of A.
baumannii from 100 hospitalized patients at Maharaj Nakorn
Chiang Mai hospital, Thailand also observed that 46% of the
isolates were pandrug-resistant and the overall mortality
was 52%.6
Over the past few years there have been reports on
treating patients infected with MDR A. baumannii and P.
aeruginosawith polymyxin B and colistin.7—9 They found that
polymyxin B and colistin had modest efficacy and were safe.
In vitro activity of polymyxin B and colistin against 100
clinical isolates of MDR A. baumannii and 100 isolates of P.
aeruginosa collected from the patients hospitalized at Sir-
iraj Hospital from 2002 and 2003, revealed that all isolates
were susceptible to polymyxin B and colistin.10 However
polymyxins are not available in Thailand and international
pharmaceutical companies do not have a policy to import
polymyxins to Thailand. Therefore we asked a local phar-
maceutical company to produce colistin and this product has
been approved by the Thai Food and Drug Administration
since 2004.
The objective of this study was to determine the efficacy
and safety of colistin produced by a local pharmaceutical
company in Thailand for the treatment of infections caused
by MDR P. aeruginosa and A. baumannii.
Methods
The study was approved by the ethics committee on human
research of the Faculty of Medicine Siriraj Hospital, and all
participating subjects signed the informed consent form. This
was a pragmatic clinical trial conducted at Siriraj Hospital,
Bangkok, Thailand, between January 2005 and April 2006.
The eligible subjects were hospitalized patients over the age
of 18 years who were infected with A. baumannii or P.
aeruginosa resistant to beta-lactams, fluoroquinolones and
aminoglycosides. We excluded patients with infections
caused by A. baumannii or P. aeruginosa with other bacteria
from our study because we felt that it was difficult to
determine the efficacy of colistin for treatment of infections
caused by MDR A. baumannii or P. aeruginosa. Colistin wasoffered to all such patients and if the patients and their
responsible physicians agreed to have colistin treatment, the
patients received intravenous colistin (colistimethate
sodium) of 5 mg/kg/day in two divided doses. The dosage
of colistin was adjusted according to the patients’ renal
function.11 If the patients or their responsible physicians
did not wish to join the study, they received other antibiotics
according to their physicians’ decisions and these patients
were defined as the ‘non-colistin group’.
All isolates of A. baumannii and P. aeruginosa from the
eligible patients were tested for colistin susceptibility by E-
test according to the manufacturer’s guidelines (AB Biodisk,
Sweden). A suspension of each isolate in Mueller—Hinton
broth (BBL-Becton Dickinson, USA), adjusted to the density
of a 0.5 McFarland standard, was swabbed in three directions
to ensure uniform growth onto Mueller—Hinton agar (BBL-
Becton Dickinson, USA) plates. Once the agar surface was
completely dry, an E-test colistin strip (ranging from 0.06 to
1024 mg/ml) was applied to each plate and the plates were
incubated at 35 8C for 16—20 hours. The minimum inhibitory
concentration (MIC) was read where inhibition of growth
intersected the E-test strip. Quality control strains of Escher-
ichia coli ATCC 25922 and P. aeruginosa ATCC 27853were used
with the reference MIC range of 0.125—0.5 and 0.5—2 mg/l,
respectively. The susceptible isolate was defined as having a
MIC of 2 mg/l. Quantitative colistin serum level was deter-
mined by microbiological assay.12
The primary outcomes were the clinical response and 30-
day mortality. A good clinical response referred to a combi-
nation of clinical cure and clinical improvement. Clinical
cure was defined as a disappearance of symptoms and signs
of infection and clinical improvement was defined as a
partial resolution of the symptoms and signs of infection.
The secondary outcomes were microbiological response and
adverse effects. Successful microbiological response was
defined as an eradication of the causative organisms at
the end of treatment. Nephrotoxicity was defined as an
increase in serum creatinine of at least two-fold of the
baseline value or a 30% decrease of creatinine clearance
from the baseline value.
Results
Between January 2005 and April 2006, 93 patients met the
inclusion criteria. Seventy-eight patients were in the colistin
group and 15 patients in the non-colistin group. The baseline
characteristics of the patients are shown in Table 1. The
mean age, gender, underlying conditions, and severity of
illness of the patients in both groups were not significantly
different.
Presenting infections in the colistin group were: pneumo-
nia (54), bacteremia and/or catheter related infection (9),
intra-abdominal infection (5), urinary tract infection (4), skin
and soft tissue infection (5), and sinusitis (1). In the colistin
group, 71 patients (91%) were infectedwith A. baumannii and
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Table 1 Baseline characteristics of the patients
Characteristic Colistin group (N = 78) Non-colistin group (N = 15)
Male 45 (57.7%) 11 (73.3%)
Mean age, years (range) 63.5 (18—103) 58.9 (27—90)
ICU admission 45 (57.7%) 5 (33.3%)
Mechanical ventilation 62 (79.5%) 14 (93.3%)
Mean APACHE II score 21.9 22.3
Pre-existing renal impairment (serum creatinine 1.5 mg/dl) 37.2% 40%
Pathogenic organism
Acinetobacter baumannii 71 (91.0%) 12 (80%)
Pseudomonas aeruginosa 7 (9.0%) 3 (20%)
Underlying condition
Diabetes mellitus with or without other medical conditions 16 (20.5%) 1 (6.7%)
Cardiovascular diseases 3 (3.9%) 3 (20%)
Cancers 6 (7.7%) 1 (6.7%)
Immunosuppressive treatment 4 (5.1%) —
Cerebrovascular diseases 7 (9.0%) —
Chronic obstructive pulmonary disease 7 (9.0%) —
Other chronic medical conditions 12 (15.4%) 4 (26.7%)
Traumatic surgical patients 10 (12.8%) 4 (26.7%)
Recent cardiovascular surgery 8 (10.3%) 2 (13.3%)
Recent brain surgery 4 (5.1%) —
Recent abdominal surgery 1 (1.3%) —seven (9%) were infected with P. aeruginosa, whereas 12
patients (80%) were infected with A. baumannii and three
(20%) were infected with P. aeruginosa in the non-colistin
group. In vitro susceptibility tests determined by E-test
revealed that all A. baumannii and P. aeruginosa isolates
had a MIC of colistin less than 2 mg/l and were considered
susceptible to colistin. In the colistin group, 33 patients
(42.3%) received colistin alone, whereas 45 patients
(57.7%) received colistin with other antibiotics including
vancomycin, aminoglycosides, metronidazole or carbape-
nems. In the non-colistin group, the patients received car-
bapenems (6), cefoperazone/sulbactam (3), cefoperazone/
sulbactam combined with netilmicin (4), and cefoperazone/
sulbactam combined with carbapenem (2).
The treatment outcomes are shown in Table 2. Sixty-four
patients (82.1%) in the colistin group had a good clinical
response. The clinical response in the patients who received
colistin alone was 84.8% and in those who received colistin
with other antibiotics was 77.8%; only four patients (26.7%) in
the non-colistin group responded.
All cause mortality within 30 days was 46.2% in the colistin
group and 80% in the non-colistin group ( p = 0.03). The
relative risk of death in the colistin group was 0.58 of the
non-colistin group with a 95% confidence interval (CI) of 0.41Table 2 Treatment outcomes of the patients
Outcome Colistin group (N = 7
Good clinical response 63 (80.8%)
All cause mortality within 30 days 36 (46.2%)
Microbiological response 74 (94.9%)
Nephrotoxicity 24 (30.8%)
Neurotoxicity 0to 0.82. The difference in mortality was statistically signifi-
cant and the number needed to treat (NNT) was approxi-
mately three, which implies that only three patients infected
with MDR A. baumannii or P. aeruginosa needed to be treated
with colistin in order to prevent one additional death. The
overall mortality rates of the patients infected with A.
baumannii and P. aeruginosa in the colistin group were
46.5% and 42.9%, respectively.
A microbiological response was found in 94.9% of the
patients in the colistin group and none in the non-colistin
group. Nephrotoxicity was observed in 24 patients (30.8%) in
the colistin group. The incidence of nephrotoxicity of the
patients in the colistin group was significantly less than that
in the non-colistin group. Seventeen (70.8%) of 24 patients in
the colistin group who developed nephrotoxicity had other
predisposing factors contributing to a decline in renal func-
tion including nephrotoxic drugs, chronic kidney diseases,
and hypovolemia. Nephrotoxic effects were mild and rever-
sible without requiring renal replacement therapy. No neu-
rotoxicity or drug reaction was observed in the patients who
received colistin. The average dose of colistin was 179.6 mg/
day, the average duration of colistin treatment was 11.9
days, and the average total dose of colistin was 2.1 g/
patient/course.8) Non-colistin group (N = 15) p Value
4 (26.7%) <0.001
12 (80%) 0.03
0 <0.001
10 (66.7%) 0.02
0
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This study used colistimethate sodium (also called colistin
methanesulfate, pentasodium colistimethane sulfate, or
colistin sulfonyl methate), which is less potent and less toxic
than colistin sulfate.13,14 Colistin has a narrow spectrum of
antimicrobial activity and is active against most aerobic
Gram-negative bacilli including P. aeruginosa and Acineto-
bacter spp, even the organisms that are multidrug-resis-
tant.13 Several reports published during the period 1999 to
2003 revealed that polymyxins were effective and safe for
treatment of patients infected with MDR Gram-negative
bacteria including A. baumannii and P. aeruginosa.7—9 We
therefore attempted to study the efficacy and safety of
locally produced colistin.
We were unable to do a randomized controlled study to
compare colistin with other antibiotics since it would be
unethical to provide antibiotics likely to be ineffective to
patients, while the antibiotic active against the causative
pathogens, colistin, was available. Therefore we had to
offer colistin to all patients who had infections caused by
A. baumannii or P. aeruginosa resistant to beta-lactams,
fluoroquinolones and aminoglycosides. However, the base-
line characteristics of the patients including mean age,
gender, underlying conditions, severity of illness and the
sites of infections of the patients in both groups were
comparable.
The results from our study also showed a good clinical
outcome and less overall mortality in patients who received
colistin for treatment of MDR A. baumannii and P. aeruginosa.
A good clinical outcome was found in 82.1% of patients
treated with colistin no matter how the patients received
it, alone or with other antibiotics. Overall mortality
decreased from 79% in a previous study of A. baumannii
infections in the same hospital to 46.5% of the patients
infected with A. baumannii treated with colistin in this
study.5 The overall mortality in the non-colistin group in this
study was still up to 80%. Furthermore, NNT for mortality
from our study was only three, indicating that only three
patients infected with MDR A. baumannii or P. aeruginosa
needed to be treated with colistin in order to prevent one
additional death. Moreover the cost of colistin was approxi-
mately 10 to 20 times lower than that of other antibiotics
used to treat MDR A. baumannii and P. aeruginosa such as
carbapenems, cefoperazone/sulbactam, and cephalosporins
with or without aminoglycosides.
A microbiological response was observed in 74 patients
(94.9%) in the colistin group. Three patients who did not have
a microbiological response also had a good clinical outcome.
However, antibiotic susceptibility profiles of these persistent
isolates were different from those of the original isolates and
these isolates could be new colonizers. In four patients who
had no microbiological response after 72 hours of colistin
treatment, the serum levels of colistin were measured by
bioassay and the results showed that colistin levels were
adequate at 4—8 times above the MIC of the organism.
Therefore the same dose of colistin was continued for 7 days
and all patients eventually had a microbiological response.
We excluded patients with infections caused by A. baumannii
or P. aeruginosawith other bacteria from our study, therefore
the efficacy of colistin for treatment of mixed infections is
unknown.Nephrotoxicity is an important side effect of colistin. In
our study, nephrotoxicity was found in 30.8% of the patients
receiving colistin; this is comparable to the results found in
a previous report.15 Some patients in the colistin group who
developed nephrotoxicity also had other contributing fac-
tors. Nephrotoxicity in these patients was mild and rever-
sible without requiring renal replacement therapy. Some
patients had improvement in their renal function after
colistin treatment, which implies that the worsening of
renal function was probably due to a severe infection or
other conditions. The incidence of nephrotoxicity of the
patients in the non-colistin group was significantly more
than that in the colistin group. This observation might be
due to uncontrolled infections and the side effects of
medications including antibiotics given to the patients.
No neurotoxicity or drug reaction was observed in the
patients in our series.
Although the ability of Gram-negative bacteria to
develop resistance to colistin is rare, such Gram-negative
bacteria can develop resistance to colistin throughmutation
or adaptation mechanisms.13,16 We therefore recommend
that colistin, as the only currently available drug for the
treatment of MDR Gram-negative bacteria in Thailand,
should be reserved for treatment of infections caused by
multidrug-resistant Gram-negative bacteria that are only
susceptible to colistin.
In summary, we found that colistin appears to be safe and
effective for treatment of infections caused by multidrug-
resistant P. aeruginosa and A. baumannii in Thai adult
patients. Treatment with colistin decreases patient mortality
and is cost-effective.
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